Skip to content

Study · Randomized controlled trial · n = 104 · 2009

6 results

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.

Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC

Clinical endocrinology6 Oct 2008Cited by 88 (Europe PMC)

PMID19178516 (opens in a new tab)DOI10.1111/j.1365-2265.2008.03441.x (opens in a new tab)PepBankPUB-19178516
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed acromegaly, initial octreotide LAR achieved success in 25% versus 49% with initial surgery at week 24, a significant difference.

    In plain wordsIn newly diagnosed acromegaly, initial octreotide had lower success than initial surgery at week twenty-four.

    Peptide
    Octreotide
    Outcome
    DecreaseSuccess at week 24
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Overall success rate
    25%
    octreotide LAR group, week 24
    Overall success rate
    49%
    surgery group, week 24
    P value
    0.047 P
    week 24 difference

    Source sentences

    Summary
    Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0.047).
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed acromegaly, initial octreotide LAR achieved success in 28% versus 39% with initial surgery at week 48, without statistical significance.

    In plain wordsIn newly diagnosed acromegaly, initial octreotide had numerically lower success than initial surgery at week forty-eight, without a significant difference.

    Peptide
    Octreotide
    Outcome
    DecreaseSuccess at week 48
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Overall success rate
    28%
    octreotide LAR group, week 48
    Overall success rate
    39%
    surgery group, week 48

    Source sentences

    Summary
    Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0.047).
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed acromegaly, tumor shrinkage >20% occurred in 73% with initial octreotide LAR versus 95% with initial surgery.

    In plain wordsIn newly diagnosed acromegaly, substantial tumor shrinkage was less frequent with initial octreotide than initial surgery.

    Peptide
    Octreotide
    Outcome
    DecreaseTumor shrinkage above 20%
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Patients with tumour shrinkage >20%
    73%
    octreotide LAR group
    Patients with tumour shrinkage >20%
    95%
    surgery group

    Source sentences

    Summary
    Both groups had a significant (> 20%) tumour shrinkage: 73% of patients in the octreotide LAR group and 95% in the surgery group.
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.
  4. 04HumanRandomized controlled trialSafety outcome

    In newly diagnosed acromegaly, gastrointestinal adverse events occurred in 71% with initial octreotide LAR versus 27% with initial surgery.

    In plain wordsIn newly diagnosed acromegaly, gastrointestinal adverse events were more frequent with initial octreotide than initial surgery.

    Peptide
    Octreotide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Gastrointestinal adverse events
    71%
    octreotide LAR group
    Gastrointestinal adverse events
    27%
    surgery group

    Source sentences

    Summary
    Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71%vs. 27%), hepatobiliary (41%vs. 8%) and respiratory (5%vs. 28%).
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.
  5. 05HumanRandomized controlled trialSafety outcome

    In newly diagnosed acromegaly, hepatobiliary adverse events occurred in 41% with initial octreotide LAR versus 8% with initial surgery.

    In plain wordsIn newly diagnosed acromegaly, liver and bile system adverse events were more frequent with initial octreotide than initial surgery.

    Peptide
    Octreotide
    Outcome
    IncreaseHepatobiliary adverse events
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Adverse events · Liver
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Hepatobiliary adverse events
    41%
    octreotide LAR group
    Hepatobiliary adverse events
    8%
    surgery group

    Source sentences

    Summary
    Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71%vs. 27%), hepatobiliary (41%vs. 8%) and respiratory (5%vs. 28%).
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.
  6. 06HumanRandomized controlled trialSafety outcome

    In newly diagnosed acromegaly, respiratory adverse events occurred in 5% with initial octreotide LAR versus 28% with initial surgery.

    In plain wordsIn newly diagnosed acromegaly, respiratory adverse events were less frequent with initial octreotide than initial surgery.

    Peptide
    Octreotide
    Outcome
    DecreaseRespiratory adverse events
    Study

    n = 104

    Comparator
    initial surgery strategy
    Analysis
    Exploratory
    Outcome group
    Adverse events · Respiratory
    Studied dose
    20 mg every 28 days, with adjustment to 30 mgAs given in this study (human).

    Measurements

    Respiratory adverse events
    5%
    octreotide LAR group
    Respiratory adverse events
    28%
    surgery group

    Source sentences

    Summary
    Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71%vs. 27%), hepatobiliary (41%vs. 8%) and respiratory (5%vs. 28%).
    2 context sentences
    Summary · context
    Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery.
    Summary · context
    In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.